Pacira BioSciences (PCRX) Competitors

Pacira BioSciences (NASDAQ:PCRX) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment.

Does the media favor PCRX or OPK?

In the previous week, Pacira BioSciences had 1 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for Pacira BioSciences and 8 mentions for OPKO Health. OPKO Health's average media sentiment score of 1.01 beat Pacira BioSciences' score of 0.57 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is PCRX or OPK more profitable?

Pacira BioSciences has a net margin of -13.07% compared to OPKO Health's net margin of -18.65%. Pacira BioSciences' return on equity of 13.42% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	-13.07%	13.42%	7.19%
OPKO Health	-18.65%	-9.76%	-6.46%

Which has better earnings and valuation, PCRX or OPK?

Pacira BioSciences has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$674.98M	1.14	$41.96M	-$2.03	-8.18
OPKO Health	$863.50M	1.30	-$188.86M	-$0.19	-8.63

Which has more risk & volatility, PCRX or OPK?

Pacira BioSciences has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Do analysts prefer PCRX or OPK?

Pacira BioSciences currently has a consensus target price of $23.50, indicating a potential upside of 41.57%. OPKO Health has a consensus target price of $2.75, indicating a potential upside of 67.68%. Given OPKO Health's stronger consensus rating and higher possible upside, analysts plainly believe OPKO Health is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
OPKO Health	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in PCRX or OPK?

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 47.3% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor PCRX or OPK?

Pacira BioSciences received 318 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 71.57% of users gave Pacira BioSciences an outperform vote while only 65.84% of users gave OPKO Health an outperform vote.

Company	Underperform	Outperform
Pacira BioSciences	Outperform Votes 823 71.57%	Underperform Votes 327 28.43%
OPKO Health	Outperform Votes 505 65.84%	Underperform Votes 262 34.16%

Summary

Pacira BioSciences beats OPKO Health on 10 of the 18 factors compared between the two stocks.